Press release
Groundbreaking Parkinson's Disease Clinical Trials to Revolutionize Parkinson's Disease Treatment: A Comprehensive Analysis by DelveInsight | Biogen, Denali Therapeutics Inc, Luye Pharma Group Ltd, Beijing Bozhiyin T&S Co., Ltd, Eli Lilly and Company, and
Parkinson's Disease Pipeline
In the Parkinson's Disease Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Parkinson's Disease NDA approvals (if any), and product development activities comprising the technology, Parkinson's disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Parkinson's Disease pipeline treatment landscape of the report, click here @ Parkinson's Disease Pipeline- https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Parkinson's Disease Pipeline Report
• DelveInsight's Parkinson's Disease Pipeline analysis depicts a robust space with 140+ active players working to develop 150+ pipeline treatment therapies.
• The leading Parkinson's Disease Companies working in the market include Biogen, Denali Therapeutics Inc, Luye Pharma Group Ltd, Beijing Bozhiyin T&S Co., Ltd, Eli Lilly and Company, Prevail Therapeutics, Parexel, Kainos Medicine Inc, Voyager Therapeutics, Sangamo Therapeutics, Ceregene, Novartis, Orion Corporation, Amgen, Medtronic, Hoffmann-La-Roche, Takeda, AstraZeneca, Ionis Pharmaceuticals Inc, AbbVie, Quintiles Inc, Abbott, Teva Pharmaceutical, and others.
• Promising Parkinson's Disease Pipeline Therapies in the various stages of development include BIIB122, Rotigotine, extended-release microspheres, LY03003 ( Rotigotine, extended-release microspheres), Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, Methylprednisolone, Sirolimus, KM-819, Carbidopa/levodopa/entacapone, Prasinezumab, MEDI1341, Levodopa-Carbidopa, RO7046015, ABT-SLV187, and others.
• On May 2023, Biogen announced a study of phase 2 clinical trials for BIIB122. BIIB122 is an investigational central nervous system-penetrant small molecule inhibitor of LRRK2 kinase.
• On July 2023, Prevail Therapeutics announced a study of phase 1 & 2 clinical trials for Methylprednisolone and Sirolimus. Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884961 are planned (Dose Level 1 and Dose Level 2). The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and clinical efficacy measures. Patients will continue to be followed for an additional 4 years to continue to monitor safety as well as selected biomarker and efficacy measures.
• On July 2023, FAScinate Therapeutics Inc announced a study of phase 2 clinical trials for KM-819. The study evaluates the safety and tolerability of multiple ascending doses of KM-819 in healthy older adults and participants with Parkinson's disease.
• On March 2023, Neurocrine Biosciences announced a study of phase 2 clinical trials for VY-AADC02. The objectives of this study are to assess the efficacy, safety and tolerability of VY-AADC02 in Patients with Parkinson's Disease with Motor Fluctuations.
Parkinson's Disease Overview
Parkinson's disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine.
To explore more information on the latest breakthroughs in the Parkinson's Disease Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Parkinson's Disease Emerging Drugs Profile
• Tavapadon: Cerevel Therapeutics
• IkT-148009: Inhibikase Therapeutics
• NLY01: Neuraly
• PT320: Peptron
Parkinson's Disease Pipeline Therapeutics Assessment
There are approx. 140+ key companies which are developing the therapies for Parkinson's disease. The Parkinson's Disease companies which have their Parkinson's disease drug candidates in the most advanced stage, i.e. phase III include, Cerevel Therapeutics.
Request a sample and discover the recent advances in Parkinson's Disease Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Parkinson's Disease Drugs and Companies
• Istradefylline (KW-6002): Kyowa Kirin Inc
• Mesdopetam (IRL790): Integrative Research Laboratories AB
• Fipamezole: Juvantia Pharma
• Piribedil: Desitin Arzneimittel GmbH
• Rasagiline mesylate: Teva Pharmaceuticals
Parkinson's Disease Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Parkinson's Disease Therapeutics Market include-
Biogen, Denali Therapeutics Inc, Luye Pharma Group Ltd, Beijing Bozhiyin T&S Co., Ltd, Eli Lilly and Company, Prevail Therapeutics, Parexel, Kainos Medicine Inc, Voyager Therapeutics, Sangamo Therapeutics, Ceregene, Novartis, Orion Corporation, Amgen, Medtronic, Hoffmann-La-Roche, Takeda, AstraZeneca, Ionis Pharmaceuticals Inc, AbbVie, Quintiles Inc, Abbott, Teva Pharmaceutical, and others.
Dive deep into rich insights for drugs for Parkinson's Disease Pipeline, click here for Parkinson's Disease Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Parkinson's Disease Pipeline Report
• Coverage- Global
• Parkinson's Disease Companies- Biogen, Denali Therapeutics Inc, Luye Pharma Group Ltd, Beijing Bozhiyin T&S Co., Ltd, Eli Lilly and Company, Prevail Therapeutics, Parexel, Kainos Medicine Inc, Voyager Therapeutics, Sangamo Therapeutics, Ceregene, Novartis, Orion Corporation, Amgen, Medtronic, Hoffmann-La-Roche, Takeda, AstraZeneca, Ionis Pharmaceuticals Inc, AbbVie, Quintiles Inc, Abbott, Teva Pharmaceutical, and others.
• Parkinson's Disease Pipeline Therapies- BIIB122, Rotigotine, extended-release microspheres, LY03003 ( Rotigotine, extended-release microspheres), Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, Methylprednisolone, Sirolimus, KM-819, Carbidopa/levodopa/entacapone, Prasinezumab, MEDI1341, Levodopa-Carbidopa, RO7046015, ABT-SLV187, and others.
• Parkinson's Disease Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Parkinson's Disease Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Parkinson's Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Parkinson's Disease - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Tavapadon: Cerevel Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Prasinezumab : Roche
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. MEDI1341: AstraZeneca
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Neural microtissues: Treefrog Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Parkinson's Disease Key Companies
21. Parkinson's Disease Key Products
22. Parkinson's Disease- Unmet Needs
23. Parkinson's Disease- Market Drivers and Barriers
24. Parkinson's Disease- Future Perspectives and Conclusion
25. Parkinson's Disease Analyst Views
26. Parkinson's Disease Key Companies
27. Appendix
List of Top Selling Market Research Reports in 2023
https://www.delveinsight.com/report-store/alcoholic-hepatitis-market
https://www.delveinsight.com/report-store/b-cell-maturation-antigen-targeted-therapies-market
https://www.delveinsight.com/report-store/blastomycosis-market
https://www.delveinsight.com/report-store/chronic-pulmonary-infections-due-to-pseudomonas-aeruginosa-in-patients-with-cystic-fibrosis-market
https://www.delveinsight.com/report-store/c-x-c-chemokine-receptor-inhibitors-competitive-landscape-market-and-pipeline-analysis
https://www.delveinsight.com/report-store/digestive-system-fistula-market
https://www.delveinsight.com/report-store/fertility-monitoring-devices-fertility-testing-devices-market
https://www.delveinsight.com/report-store/hay-fever-conjunctivitis-market
https://www.delveinsight.com/report-store/kawasaki-disease-market
https://www.delveinsight.com/report-store/myopia-progression-market
https://www.delveinsight.com/report-store/pecoma-market
https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market
https://www.delveinsight.com/report-store/percutaneous-arterial-closure-device-market
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
https://www.delveinsight.com/report-store/upper-tract-urothelial-cancer-market
https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
https://www.delveinsight.com/report-store/supraventricular-tachycardia-market
https://www.delveinsight.com/report-store/stem-cell-market
https://www.delveinsight.com/report-store/soft-tissue-defect-market
https://www.delveinsight.com/report-store/small-lymphocytic-lymphoma-market
https://www.delveinsight.com/report-store/shigella-infections-market
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/radiation-retinopathy-market
https://www.delveinsight.com/report-store/primary-biliary-cholongitis-pbc-market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Groundbreaking Parkinson's Disease Clinical Trials to Revolutionize Parkinson's Disease Treatment: A Comprehensive Analysis by DelveInsight | Biogen, Denali Therapeutics Inc, Luye Pharma Group Ltd, Beijing Bozhiyin T&S Co., Ltd, Eli Lilly and Company, and here
News-ID: 3142633 • Views: …
More Releases from DelveInsight Business Research
Peripheral T-Cell Lymphoma (PTCL) Market Analysis 2034 - Competitive Landscape, …
The Peripheral T-Cell Lymphoma (PTCL) Market across the 7MM was valued at approximately USD 680 million in 2020, and it is projected to experience steady growth by 2034.
Peripheral T-Cell Lymphoma (PTCL) Market Overview
As of 2023, the United States held the largest share of the PTCL therapeutics market within the 7MM, reaching a valuation of around USD 500 million, followed by Japan. Newly diagnosed patients are generally managed with anthracycline-based chemotherapy…
Nontuberculous Mycobacterial Infection Market Analysis 2034 - Competitive Landsc …
In 2023, the Nontuberculous Mycobacterial (NTM) Infections Market in the United States was valued at around USD 360 million, and it is projected to grow throughout the 2024-2034 forecast period.
Nontuberculous Mycobacterial Market Overview
The NTM infections market is anticipated to expand consistently between 2024 and 2034, fueled by advancements in diagnostics, the introduction of novel therapies, and growing disease awareness. The aging population, which is more susceptible to NTM infections, continues…
Lupus Nephritis Market Analysis 2034 - Competitive Landscape, Clinical Trials, M …
The Lupus Nephritis (LN) market was valued at approximately USD 1.8 billion in 2024 and is projected to expand steadily from 2025 to 2034, driven by the introduction of emerging therapies across the seven major markets (7MM).
Lupus Nephritis Market Summary
In Japan, the Lupus Nephritis market size was around USD 49 million in 2024, and it is anticipated to grow throughout the forecast period (2025-2034). Lupus Nephritis, a serious complication of…
Sjogren's Syndrome Market Outlook 2034 - Clinical Trials, Market Size, Medicatio …
Prominent Sjogren's syndrome companies include Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson & Johnson, and several others.
Sjogren's Syndrome Market Summary
In 2023, the Sjogren's syndrome market size across the seven major markets (7MM) was valued at approximately USD 1.9 billion and is expected to witness steady growth through 2034.
Sjogren's syndrome is an autoimmune disease that primarily disrupts the salivary…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.43 billion…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
